The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT
Tóm tắt
Từ khóa
Tài liệu tham khảo
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–62. https://doi.org/10.1056/NEJMra1713263.
Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019.
Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2016;2(April):16018. https://doi.org/10.1038/nrdp.2016.18.
Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56(2):464–73. https://doi.org/10.1016/j.jhep.2011.07.012.
Sangro B. Chemoembolization and radioembolization. Best Pract Res Clin Gastroenterol. 2014;28(5):909–19. https://doi.org/10.1016/j.bpg.2014.08.009.
Mantry PS, Mehta A, Madani B, Mejia A, Shahin I. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol. 2017;8(5):799–807. https://doi.org/10.21037/jgo.2017.08.03.
Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36. https://doi.org/10.1016/S1470-2045(17)30683-6.
Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66(3):792–800. https://doi.org/10.1016/j.ijrobp.2006.05.065.
Chow PKH, Gandhi M, Tan S-B, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018. https://doi.org/10.1200/jco.2017.76.0892.
Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90 Y-microspheres. J Nucl Med. 2000;41:1673–81.
Kulik LM, Atassi B, Van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol. 2006. https://doi.org/10.1002/jso.20609.
Carr BI. Yttrium glass microspheres (therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transplant. 2004;10:S107–10. https://doi.org/10.1002/lt.20036.
de la Torre MA, Buades-Mateu J, de la Rosa PA, et al. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver Int. 2016;36(8):1206–12. https://doi.org/10.1111/liv.13098.
Bolondi L, Burroughs AK, Dufour J. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348–59.
Iñarrairaegui M, Martinez-Cuesta A, Rodríguez M, et al. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010. https://doi.org/10.1016/j.ijrobp.2009.07.006.
Bilbao JI, Garrastachu P, Herraiz M, et al. Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors. Cardiovasc Intervent Radiol. 2010. https://doi.org/10.1007/s00270-009-9717-1.
Fernandez-Ros N, Iñarrairaegui M, Paramo JA, et al. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver Int. 2015. https://doi.org/10.1111/liv.12592.
Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement 4):iv238–55. https://doi.org/10.1093/annonc/mdy308.
Bruix J, Raoul J-L, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9. https://doi.org/10.1016/j.jhep.2012.06.014.
Bruix J, Reig M, Sangro B. Assessment of treatment efficacy in hepatocellular carcinoma: response rate, delay in progression or none of them. J Hepatol. 2017;66(6):1114–7. https://doi.org/10.1016/j.jhep.2017.02.032.
Reig M, Bruix J. Pattern of tumor progression in liver cancer: the missing partner in trial design. Hepatology. 2015;62(3):674–6. https://doi.org/10.1002/hep.27881.
Ogasawara S, Chiba T, Ooka Y, et al. Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. Invest New Drugs. 2016;34(2):255–60. https://doi.org/10.1007/s10637-016-0323-1.
Eisenhauer E, Therasse P, Bogaerts J. New response evaluation criteria in solid tumours—revised RECIST Guideline (version 11). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.
Reig M, Rimola J, Torres F, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology. 2013;58(6):2023–31. https://doi.org/10.1002/hep.26586.
Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the albi grade. J Clin Oncol. 2015;33(6):550–8. https://doi.org/10.1200/JCO.2014.57.9151.
Gardini AC, Scarpi E, Faloppi L, et al. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2014;7(41):67142–9. https://doi.org/10.18632/oncotarget.11565.
Lué A. Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. Oncotarget. 2017;8(61):103077–86.
Petrell F, Barni S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol. 2013;24(1):186–92. https://doi.org/10.1093/annonc/mds289.
Hayashi H, Okamoto I, Taguri M, Morita S, Nakagawa K. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. Clin Lung Cancer. 2013;14(3):261–6. https://doi.org/10.1016/j.cllc.2012.09.006.
Shimokawa M, Okhi M, Kaku T. Correlation of progression-free and post-progression survival with overall survival in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer. Eur J Gynaecol Oncol. 2015;36(4):370–5.
Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology. 2018;68(4):1429–40. https://doi.org/10.1002/hep.29691.
Mazzaferro V, Sposito C, Bohoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013. https://doi.org/10.1002/hep.26014.
Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64. https://doi.org/10.1053/j.gastro.2009.09.006.